Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 41, Issue 8


Analytical and Clinical Evaluation of a New Urinary Tumor Marker: Bladder Tumor Fibronectin in Diagnosis and Follow-up of Bladder Cancer

Nilgun Mutlu / Levent Turkeri / Kaya Emerk
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2003.165


Bladder cancer is the fourth most common malignant neoplasm in men and the tenth most common in women. Cystoscopy presents the gold standard for detection and monitoring of bladder cancer. However, it is an invasive and expensive procedure. Therefore, development of biomarkers for the purposes of screening, diagnosis and prediction of the prognosis in bladder cancer is required. Bladder tumor fibronectin is one of the new urinary tumor markers. The aim of this study is to evaluate the diagnostic performance of urinary bladder tumor fibronectin in detecting and monitoring bladder cancer. A total of 75 patients with the diagnosis of bladder cancer, 20 patients with the diagnosis of benign prostatic hyperplasia, 7 patients with the diagnosis of prostate cancer between the years 1996–2000, and 28 age-matched healthy individuals, were enrolled in the study. The patients were diagnosed by cystoscopy, with histopathological evaluation of the tumor, as having superficial or invasive bladder cancer. Patients were followed-up clinically with data pertinent to disease recurrence and progression. Bladder tumor fibronectin (BTF; ng/ml) was determined by solid phase, two-site chemiluminescent immunometric commercial diagnostic assay developed for the Immulite automated immunoassay system (Diagnostic Products Corporation, Los Angeles, CA, USA). All measured values were normalized by urinary creatinine, and the obtained data were evaluated by receiver-operating characteristics (ROC) curve analysis. Optimal cut-off was established at 43.4 ng/mg. This cut-off rendered overall sensitivities of 72% and specificity of 82.1%. The analytical evaluation of the BTF test displayed promising results in terms of a non-invasive in vitro test in the diagnosis of bladder cancer. Although it was not satisfactory in prediction of recurrence or progression of the disease, it correlated well with the stage, one of the most reliable prognostic factors. In conclusion, the urinary bladder tumor fibronectin test warrants further clinical evaluation.

About the article

Published Online: 2005-06-01

Published in Print: 2003-08-07

Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 41, Issue 8, Pages 1069–1074, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.165.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Fengbin Gao, Tianyuan Xu, Xianjin Wang, Shan Zhong, Shanwen Chen, Minguang Zhang, Xiaohua Zhang, Yifan Shen, Xiaojing Wang, Chen Xu, and Zhoujun Shen
Journal of Experimental & Clinical Cancer Research, 2017, Volume 36, Number 1
Rachel L. Darr, Kathleen J. Savage, Mark Baker, Gregory E. Wilding, Amy Raswalsky, Todd Rideout, Richard W. Browne, and Peter J. Horvath
Growth Hormone & IGF Research, 2016, Volume 30-31, Page 45
Jamie J. D’Costa, James C. Goldsmith, Jayne S. Wilson, Richard T. Bryan, and Douglas G. Ward
Bladder Cancer, 2016, Volume 2, Number 3, Page 301
Brian Keith McNeil and Robert H Getzenberg
Expert Opinion on Medical Diagnostics, 2009, Volume 3, Number 3, Page 263
Xiaorong Yang, Huang Huang, Zongyue Zeng, Liuyang Zhao, Ping Hu, Dali He, Xi Tang, and Zhaofang Zeng
Clinical Biochemistry, 2013, Volume 46, Number 15, Page 1377
Stephanie I. K. Lemberger, Cornelia A. Deeg, Stefanie M. Hauck, Barbara Amann, Sieglinde Hirmer, Katrin Hartmann, and Roswitha Dorsch
American Journal of Veterinary Research, 2011, Volume 72, Number 10, Page 1407
Violeta Menéndez, Antonio Fernández-Suárez, Juan Antonio Galán, Miguel Pérez, and Francisco García-López
Urology, 2005, Volume 65, Number 2, Page 284
Masaaki Iwatsuki, Koshi Mimori, Takehiko Yokobori, Hideshi Ishi, Toru Beppu, Shoji Nakamori, Hideo Baba, and Masaki Mori
Cancer Science, 2010, Volume 101, Number 2, Page 293
Liao-Yuan Li, Ming Yang, Hai-Bin Zhang, Xi-Kang Su, Wen-Feng Xu, Yong Chen, Zhou-Jun Shen, and Xin Gao
BJU International, 2008, Volume 102, Number 5, Page 566

Comments (0)

Please log in or register to comment.
Log in